Efficacy

Proven to significantly increase Hgb and iron levels across the spectrum of CKD^1,2

The efficacy of Feraheme in adult chronic kidney disease (CKD) patients with iron deficiency anemia (IDA) was assessed in 3 randomized, open-label, controlled clinical trials: 2 trials conducted in non-dialysis dependent CKD (NDD-CKD) patients and 1 trial conducted in hemodialysis dependent CKD (HDD-CKD) patients.^a

• In all 3 trials, patients were randomized to treatment with Feraheme or oral iron^1,2
• Feraheme was administered as two 510-mg IV single doses; most patients received their second Feraheme injection 3 to 8 days after the first injection
• Oral iron (ferrous fumarate) was administered as a total daily dose of 200 mg elemental iron daily for 21 days
• In all 3 trials, two 510-mg doses of Feraheme were significantly more effective than oral iron in raising hemoglobin (Hgb) and iron indices^1,2
• Following completion of the controlled phase of each of these trials, patients with persistent IDA could receive 2 additional 510-mg IV injections of Feraheme for a total cumulative dose of 2.04 g¹

^a Hgb was the primary efficacy endpoint and transferrin saturation (TSAT) was an additional efficacy endpoint in 3 randomized, open-label, controlled clinical trials.²

Important Safety Information

Indication and contraindications

Feraheme is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme is contraindicated in patients with evidence of iron overload, known hypersensitivity to Feraheme or any of its components, and patients with anemia not caused by iron deficiency.

Warnings and precautions

In clinical studies, serious hypersensitivity reactions were reported in 0.2% (3/1,726) of subjects receiving Feraheme. Other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria or wheezing) were reported in 3.7% (63/1,726) of subjects. Patients should be observed for signs and symptoms of hypersensitivity for at least 30 minutes following Feraheme injection and the drug should only be administered when personnel and therapies are readily available for the treatment of hypersensitivity reactions. 1.9% (33/1,726) of Feraheme-treated subjects experienced hypotension. Please monitor for signs and symptoms of hypotension following each Feraheme injection. Excessive therapy with parenteral iron can lead to excess storage of iron with the possibility of iatrogenic hemosiderosis. Patients should be regularly monitored for hematologic response during parenteral iron therapy, noting that lab assays may overestimate serum iron and transferrin bound iron values in the 24 hours following administration of Feraheme. As a superparamagnetic iron oxide, Feraheme may transiently affect magnetic resonance diagnostic imaging studies for up to 3 months following the last Feraheme dose. Feraheme will not affect X-ray, CT, PET, SPECT, ultrasound, or nuclear imaging.

Adverse reactions

In clinical trials, the most commonly occurring adverse reactions in Feraheme treated patients versus oral iron treated patients reported in ≥2% of chronic kidney disease patients were diarrhea (4.0% vs. 8.2%), nausea (3.1% vs. 7.5%), dizziness (2.6% vs. 1.8%), hypotension (2.5% vs. 0.4%), constipation (2.1% vs. 5.7%) and peripheral edema (2.0% vs. 3.2%). In clinical trials, adverse reactions leading to treatment discontinuation and occurring in 2 or more Feraheme-treated patients included hypotension, infusion site swelling, increased serum ferritin level, chest pain, diarrhea, dizziness, ecchymosis, pruritus, chronic renal failure, and urticaria.

Please see full Prescribing Information for Feraheme.